Liu K, Zhu Y, Zhou Y, Zhang Y, et al. Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis. Gynecol Oncol 2022 Jun 30. pii: S0090-8258(22)00419.
PMID: 35781166